Stille AB
STO:STIL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (5.7), the stock would be worth kr193.37 (20% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.1 | kr241.5 |
0%
|
| 3-Year Average | 5.7 | kr193.37 |
-20%
|
| 5-Year Average | 6.7 | kr226.16 |
-6%
|
| Industry Average | 3.9 | kr132.61 |
-45%
|
| Country Average | 5.6 | kr190.39 |
-21%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
S
|
Stille AB
STO:STIL
|
2.2B SEK | 7.1 | 39 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 23.4 | 56.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 6.3 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 8.1 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 5.2 | 22.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 6.6 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 8.9 | 43 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 16.7 | 41.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 5.1 | 18.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 5.7 | 23.5 | |
| US |
|
Resmed Inc
NYSE:RMD
|
30.9B USD | 9.1 | 20.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 3.3 |
| Median | 5.6 |
| 70th Percentile | 9.2 |
| Max | 18 023.5 |
Other Multiples
Stille AB
Glance View
Stille AB engages in the development and sale of medical equipment. The company is headquartered in Torshaella, Sodermanlands. The product portfolio is divided into two business lines. The Surgery business area develops, produces and markets handcrafted, forged surgical instruments for all fields of open surgery, with an emphasis on cardiovascular surgery, and reconstructive and aesthetic plastic surgery. Its products include scissors, forceps, artery forceps, needle holders and clamps, among others. The Patient Positioning area develops and manufactures two main groups of procedure-specific specialized tables for cardiovascular surgery and gynecology, urology and urodynamic examinations. As of December 31, 2011, the Company had two wholly owned subsidiaries, Stille Surgical Inc. and Stille Incentive AB. As of December 30, 2011, the it's largest shareholder was Linc Invest AB (39.81%). On September 2, 2013, the Company sold its business unit, Sonesta, to ADDvise Lab Solutions publ AB.
